CA2 and Cowden disease: The first observational study of anti-TNF drugs involved the treatment of 10 patients with refractory CD using the monoclonal antibody ca2, which reduced inflammation by blocking TNF, showing remarkably significant clinical efficacy (Van Dullemen et al., 1995).